Gene silencing via CpG island methylation in the promoter region is one of the mechanisms by which tumor suppressor genes are inactivated in human cancers. Previous studies have shown that the tissue inhibitors of metalloproteinases (TIMP)-2 gene, which is an endogenous inhibitor of matrix metalloproteinases involved in cell invasion and tumorigenesis, is downregulated or silenced in a variety of human cancer cell lines. Here, we investigated the mechanism underlying TIMP-2 expression in prostate cancer cell lines and primary prostate tumor samples. We observed a strong correlation between promoter hypermethylation and lost expression of TIMP-2 gene, which was supported by other results demonstrating that promoter demethylation by 5-aza-2 0 -deoxycytidine and trichostatin A reactivated TIMP-2 and restored its expression in TIMP-2-silenced metastatic prostate cell lines. These results were further substantiated by a chromatin immunoprecipitation assay, showing the preferential binding of MeCP2 to methylated CpG island in TIMP-2-silenced metastatic prostate cell lines. In vitro Matrigel invasion assays showed that re-expression of TIMP-2 after a combined treatment with 5-aza and trichostatin-A in metastatic prostate cells resulted in a significant reduction of tumor cell invasion. Furthermore, CpG methylation of TIMP-2 promoter was also shown in primary prostate tumors that expressed decreased TIMP-2 protein levels. These results suggest that the downregulation of the TIMP-2 gene is associated with promoter methylation and that this may play an important role in prostate cancer progression during the invasive and metastatic stages of the disease.
Introduction
Prostate cancer remains the most commonly diagnosed solid tumor and is the second leading cause of cancer death in men in the United States (Jemal et al., 2003) . It is a heterogenous disease, varying from clinically indolent to a rapidly fatal systemic malignancy. Prostate cancer develops to an advanced stage in B25% of patients (Jemal et al., 2004) . Androgen ablation remains the primary treatment for advanced prostate cancer, but hormone-refractory prostate cancer recurs invariably within 1-2 years (Kasamon and Dawson, 2004) . Currently, there is no curative therapy for the advanced or hormone-refractory prostate cancer (Hegeman et al., 2004) . Improved understanding of the molecular mechanisms of prostate cancer progression may provide a novel basis for development of effective treatment strategies.
Matrix metalloproteinases (MMPs) are a family of structurally related proteolytic enzymes that mediate degradation of the extracellular matrix and the basement membrane (Liotta et al., 1980; Rao, 2003) . High levels of MMP activity have been linked to tumor growth, invasion and tumor-induced angiogenesis (Yamamoto et al., 1996; Gokaslan et al., 1998) . Net MMP activity is the result of the balance between the levels of the activated enzyme and tissue inhibitors of metalloproteinases (TIMPs) . TIMPs belong to a family of natural inhibitors that control the activity of MMP (Gomez et al., 1997) . Four members of this family have been identified: TIMP-1, TIMP-2, TIMP-3 and TIMP-4. All four TIMPs inhibit active forms of most MMPs, but some differences in their inhibitory properties have been reported (Nagase, 1998) . TIMPs are involved in diverse biological processes including cell growth, tumor progression, apoptosis, invasion, metastasis and angiogenesis (Gomez et al., 1997; Valente et al., 1998) . TIMP-2 is one of the most frequently investigated members of the group owing to its involvement in cancer progression and metastasis (DeClerck et al., 1992; Imren et al., 1996) . Epigenetic inactivation of tumor suppressor genes (TSGs) or tumor-related genes by hypermethylation in the promoter region is a common event in human tumor cell lines and human cancers. Several TSGs are inactivated by this mechanism (Esteller et al., 2001) . We have demonstrated previously that the TIMP-2 gene is expressed in normal human tissues, whereas its expression is downregulated in glioblastomas and metastatic lung tumors (Mohanam et al., 1995) . Overexpression of TIMP-2 has been shown to restrict the invasiveness of various tumor cell types in vitro (DeClerck et al., 1992; Valente et al., 1998) . In addition, TIMP-2 overexpression had inhibitory effects on tumor growth and angiogenesis in a breast cancer mouse model (Hajitou et al., 2001) . Taken together, these characteristics strongly suggest an anti-tumor function of the TIMP-2 gene in cancer progression.
In this study, we investigated the methylation patterns of the TIMP-2 gene promoter in prostate cell lines and primary prostate tumors. Our results show, for the first time, CpG island methylation in the TIMP-2 promoter region of a significant percentage of prostate cell lines and tumors, that did not express TIMP-2 protein indicating that epigenetic regulation is important in TIMP-2 expression in prostate tumors.
Results

TIMP-2 expression in normal, tumor and metastatic prostate cell lines
Previous studies by our group (Mohanam et al., 1995) and others (DeClerck et al., 1992; Imren et al., 1996; Valente et al., 1998) have established that TIMP expression is downregulated with increasing malignancy and that this downregulation is associated with an imbalance between the production of MMPs and TIMPs and a shift towards a pro-proteolytic state with an invasive phenotype ( Figure 1a ). In the present study, we first examined the activities of MMPs (MMP-9 and MMP-2) and TIMPs (TIMP-1 and TIMP-2) in normal, tumor and metastatic prostate cell lines by zymography and reverse zymography, respectively. As a control, we used the fibrosarcoma cell line HT1080, which expresses both TIMPs and MMPs (Yoon et al., 2001) . Gelatin zymography revealed high levels of MMP-9 and MMP-2 in the culture medium of metastatic prostate cells (LNCaP, DU145, PC3 and Tramp-C1), whereas it was undetectable in the cell culture medium from normal (RWPE1) and tumorigenic prostate cells (RWPE2) (Figure 1b, top) . Notably, reverse zymography showed no MMP-inhibitory activity in the cell culture medium from metastatic prostate cells, but intense TIMP-1 and TIMP-2 bands were observed in normal prostate cells (Figure 1b, bottom) . A similar trend was observed by immunoblot assay as well (Figure 1c) . The tumorigenic RWPE2 cell line showed TIMP-1 inhibitory activity and protein expression, but a barely visible TIMP-2 band was observed at both the activity and protein levels. Thus, TIMP-2 activity and protein levels correlated with their known metastatic potential.
To determine whether these protein expression findings correlated with the biological activity of the prostate cancer cell lines used, we measured the ability of these cells to traverse a matrigel-coated membrane with 8 mM pores, a correlate of metastatic potential in vivo. We found that LNCaP, DU145, PC3 and Tramp-C1 cells, which do not express detectable TIMP-2 protein, displayed the invasive potential, whereas RWPE1 cells, which express TIMP-2, exhibited no invasive potential (Figure 1d ). Downregulation of TIMP-2 expression is associated with promoter methylation in metastatic prostate cancer cell lines Methylation of CpG dinucleotides in the promoter region is an important mechanism that silences expression of many TSGs in cancers (Esteller et al., 2001) . As the TIMP-2 gene contains a CpG island in its promoter ( Figure 2a ), we studied whether methylation of the TIMP-2 promoter is a possible mechanism for the inactivation of TIMP-2 in metastatic prostate cell lines using methylation-specific PCR (MSP). Only unmethylated and no methylated DNA was detected in RWPE1 cells that expressed a high level of TIMP-2. In contrast, only methylated and no unmethylated DNA was detected in LNCaP, DU145, PC3 and Tramp-C1 cells that do not express TIMP-2 ( Figure 2b ). Methylated DNA was more strongly detected than unmethylated DNA in RWPE2 cells that expressed a low level of TIMP-2. These results clearly show that the TIMP-2 promoter was hypermethylated in all metastatic prostate cell lines that lack TIMP-2 expression.
TIMP-2 re-expression with 5-aza and trichostatin-A treatment To determine the contribution of the TIMP-2 promoter methylation to the expression of this gene, we treated the promoter-methylated prostate cancer cell lines with varying concentrations of 5-aza and TSA. According to the reverse transcription polymerase chain reaction (RT-PCR) results, treatment with 20 mM 5-aza for 5 days and 50 nM TSA for an additional 24 h restored an optimal level of TIMP-2 messenger RNA (mRNA) expression in metastatic prostate cells (Figure 2c , top). These changes in TIMP-2 expression following treatment with 5-aza plus TSA are consistent with the notion that promoter methylation repressed TIMP-2 expression Bisulfitemodified DNA derived from prostate cancer cell lines were amplified with TIMP-2 primers specific for unmethylated and methylated DNA. TIMP-2-U, unmethylated PCR product; TIMP-2-M, methylated PCR product; NC, no template control. Positive and negative controls were described in Materials and methods. (c) mRNA expression of TIMP-2 was analysed using RT-PCR in prostate cancer cells treated with 20 mM 5-aza-CdR followed by 50 nM TSA, as described in Materials and methods. GAPDH mRNA was amplified as a loading control and expression standard. Bar diagram showing densitometry quantified data of TIMP-2 mRNA/GAPDH mRNA ratios from three independent experiments. Asterisks (*) indicate significant differences from untreated control cells (Po0.01). (d) Assessment of MeCP2 binding on the TIMP-2 promoter by ChIP analysis. The bound MeCPs fraction (ChIP) shows binding to the TIMP-2 promoter. Aliquots of chromatin taken before immunoprecipitation were used as 'input' controls whereas chromatin eluted from immunoprecipitations lacking antibody were used as 'no antibody' (ÀAb) controls.
in metastatic prostate cells. To test for an inherent effect of this drug on TIMP-2 expression in cells that normally express TIMP-2, we also examined the effects of 5-aza plus TSA on RWPE1 cells. No significant change in TIMP-2 expression levels was observed in RWPE1 cells after drug treatment (Figure 2c, bottom) . To confirm the demethylation effect of 5-aza and TSA, bisulfite sequencing was performed on treated cell lines. The results clearly showed that the promoter was truly demethylated (data not shown). Promoter region CpG dinucleotides were mostly methylated in metastatic prostate cell lines LNCaP, DU145, PC3 and Tramp-C1, which do not express TIMP-2, whereas none of these promoter region CpG islands were hypermethylated in the TIMP-2-expressing cell line RWPE1 and 5-aza/TSA-treated cell lines LNCaP, DU145, PC3 and Tramp-C1. These data strongly suggest that hypermethylation was responsible for TIMP-2 gene silencing.
We next investigated the methyl-CpG-binding proteins (MeCPs) occupancy in the hypermethylated TIMP-2 promoter in metastatic prostate cells. It is thought that methylated CpG may be bound by MeCPs, which in turn are associated with transcription repression complexes containing mSin3A and histone deacetylase (Yu et al., 2000; Pulukuri and Rao, 2006) . Thus, we examined the association of MeCP2 with the TIMP-2 promoter region in prostate cell lines using ChIP. We found that MeCP2 were present in the TIMP-2 promoter region in metastatic prostate cell lines LNCaP, DU145, PC3 and Tramp-C1, but not in TIMP-2-expressing normal prostate cell line RWPE1 (Figure 2d ). These results suggest that MeCP2 was associated with the methylated TIMP-2 promoter, and thus, interferes with transcriptional activity of the methylated promoter.
Effects of 5-aza and TSA treatment on the invasive potential of the metastatic prostate cell lines To determine the effect of TIMP-2 promoter methylation on the invasiveness of metastatic prostate cells, the invasive potentials of control and treated DU145 and PC3 cells were determined by matrigel invasion assay. Induction of TIMP-2 expression in DU145 and PC3 cells treated with 5-aza and TSA resulted in a significant reduction of the invasive potential of these cells (Figure 3a) . Representative pictures are shown in Figure 3b . Incubation of these cells with the anti-TIMP-2 antibody blocked this acquired reduction in invasive potential (Figure 3a) . This provided further convincing evidence that this decrease in tumor cell invasion after treatment with 5-aza and TSA is due to the induction of TIMP-2 expression.
Downregulation of TIMP-2 in human prostate cancer As our data are consistent with a potential tumorsuppressive function for TIMP-2, we assessed if TIMP-2 was disturbed in human prostate cancer. To address this question, TIMP-2 expression was evaluated in the human prostate tissue using immunohistochemistry (IHC). TIMP-2 expression was classified as negative, weak and strong in 17 (41.2%), 21 (48.6%) and 4 (10.2%) tumor tissue samples, respectively ( Figure 4A ). There was a significantly lower level of TIMP-2 protein expression in the tumors than in the normal tissue samples (Po0.01, Figure 4A ) and the representative pictures were presented in Figure 4B . To further confirm these observations, immunoblot analysis was performed using four-paired human normal prostate and tumor tissue samples with known levels of TIMP-2 ( Figure 4C ). It was clear that the tumor tissue samples exhibited a downregulation of TIMP-2 protein expression as compared with the normal prostate tissue, which was consistent with the level of TIMP-2 protein expression determined by immunohistochemical staining. We also examined mRNA expression within twenty-paired human normal prostate and tumor tissue samples by real-time PCR analysis ( Figure 4D ). Consistent with the results of the IHC and immunoblotting, TIMP-2 mRNA was significantly downregulated in the majority of tumor samples when compared with their adjacent normal tissue ( Figure 4D ).
Methylation status of TIMP-2 promoter in human prostate tumors
To determine whether TIMP-2 inactivation by DNA methylation is characteristic of human prostate tumors, we performed MSP analysis with primer sets targeting the sequence around the most frequently methylated sites (Figure 2a ) in a panel of 42 human prostate tumors, 32 normal prostate and 15 benign prostatic hyperplasia (Figure 5a ). Methylated DNA was more strongly detected than unmethylated DNA in the eight other prostate tumors. In contrast, only unmethylated DNA was detected in 27 of 32 normal prostate samples (Figure 5b ). Partial methylation was detected in four of 15 BPH samples, with unmethylated DNA being more strongly detected than methylated DNA in one of these cases and the other ten BPH samples exhibited only unmethylated DNA (Figure 5c ). The methylation profile of the TIMP-2 promoter in normal, BPH and prostate tumors is summarized in Figure 5d . We further analysed the methylation status of the TIMP-2 promoter using bisulfite sequencing ( Figure 6 ). Nearly all 25 CpG sites within the CpG island of TIMP-2 were methylated in prostate tumors. In contrast, CpG sites of TIMP-2 promoter were either unmethylated or sparsely methylated in normal (Figure 6a ) and tumor-matched adjacent normal tissues (Figure 6b ). The prevalence of TIMP-2 promoter methylation in prostate tumors is strongly consistent with the lack of TIMP-2 expression seen in the majority of prostate tumors, whereas the lower frequency of promoter methylation in BPH and normal prostate samples is consistent with the presence of TIMP-2 expression in these tissues (Figures 4-6 ).
Discussion
Our studies show that methylated TIMP-2 can be detected in metastatic prostate cell lines and TIMP-2 mRNA expression can be re-established after demethylation with 5-aza and TSA (Figure 2 ). After treatment with 5-aza and TSA, an induction of TIMP-2 mRNA expression in DU145 and PC3 cells resulted in a considerable reduction of the invasive capacity of these cells. Specificity of these TIMP-2-mediated effects was shown by incubating these experimental DU145 and PC3 cells with an anti-TIMP-2 antibody that significantly reversed this acquired reduction in tumor cell invasive capacity. These results provided convincing evidence that induction of TIMP-2 expression is indeed responsible for the lower invasive capacity of these cells (Figure 3 ). Our observations are in line with the previously shown inhibitory effect of TIMP-2 on the invasive ability of fibrosarcoma HT1080 tumor cells (Yoon et al., 2001) . Our studies using clinical prostate samples have shown that majority of the prostate cancer tissues (n ¼ 42) have weak or no expression of TIMP-2 when compared with BPH or normal prostate tissues (Figure 4) . Additionally, we have shown that the downregulation of TIMP-2 in prostate cancer is owing to epigenetic control of its expression via gene promoter region hypermethylation (Figures 5 and 6 ). These findings provide further insight into earlier observations that TIMP-2 was differentially expressed in a variety of human malignant tumors (Mohanam et al., 1995) .
Previous studies on other members of the TIMP family including TIMP-3 suggest that methylation is important for the regulation of TIMP-3 expression (Bachman et al., 1999; Pennie et al., 1999) . Recent data identified downregulation of TIMP-2 expression by epigenetic mechanisms (Suzuki et al., 2002; Ivanova et al., 2004; Galm et al., 2005) . Suzuki et al. (2002) observed methylated TIMP-2 in the colorectal cancer cell line RKO. However, methylation of TIMP-2 was not commonly found in primary colorectal tumors. Ivanova et al. (2004) used MSP and sodium bisulfite analysis of genomic DNA from expressing and unexpressing cervical cancer cell lines to show a correlation between gene activity and demethylation of the 5 0 region of the TIMP-2 gene. Galm et al. (2005) recently showed that treatment of lymphoma cell line Raji and the leukemia cell line KG1a with 5-aza induced TIMP-2 gene expression. These two recent studies established the frequency of hypermethylated TIMP-2 genes in both lymphoma (38.6%) and cervical cancer (47%). In the present study, methylation of the TIMP-2 promoter was demonstrated in primary prostate samples at a high frequency (78.5%). We believe that genetic variability between the different cancers may account for the differences. Consistent with this notion, the methylation profile of individual genes seems to be different in various tumor types. Certain genes, such as 14-3-3s, RASSF1A and P16INK4a, are commonly methylated in multiple human cancers (Wajed et al., 2001; Pulukuri and Rao, 2006) , whereas others show high frequencies of methylation only in specific tumors. One example is the GSTP1 gene that is highly methylated in breast and prostate cancers but is largely unmethylated in other types of tumors (Esteller et al., 2001; Das and Singal, 2004) .
In summary, the present study shows that hypermethylation of the TIMP-2 gene correlates with the silencing of TIMP-2 expression in prostate cancer cell lines and in primary prostate tumors. Further studies of methylation profiles of a large number of primary tumor samples will provide important insight into the role of CpG island hypermethylation of the TIMP-2 promoter in tumor progression.
Materials and methods
Cell lines, 5-aza-2 0 -deoxycytidine and trichostatin A treatment The prostate cancer cell lines RWPE1, RWPE2, LNCaP, DU145, PC3 and Tramp-C1 were obtained from the American Type Culture Collection and cultured as directed. Total RNA and genomic DNA were isolated from the treated cells using RNA and DNA isolation kits. Cells were treated with 5-aza and TSA as described previously (Pulukuri and Rao, 2006) .
Zymography
Confluent prostate cells were maintained in serum-free media for 24 h. Equal amounts of concentrated media were loaded onto 10% polyacrylamide gels containing 2.5 mg/ml of gelatin (Sigma, St Louis, MO, USA). After electrophoresis, the gels were washed and stained as described previously (Yamamoto et al., 1996) . The substrate degrading enzymes MMP-9 and MMP-2 were identified as clear bands in the blue background. For reverse zymography, concentrated media was electrophoresed in 15% polyacrylamide reverse zymograms containing 2.5 mg/ml gelatin and 0.15 mg/ml MMP-2 (Oliver et al., 1997) . TIMP activity was visualized as dark zones of gelatinase inhibition against a pale, partially digested background.
Human prostate tissues and immunohistochemistry Paired human prostate tumor and normal adjacent tissues were obtained from patients undergoing routine therapeutic surgery. Many prostate cancer, BPH and normal tissues were also obtained as paraffin-embedded, formalin-fixed blocks. For IHC, tissue sections were labelled with mouse monoclonal anti-human TIMP-2 antibody (Oncogene, San Diego, CA, USA) and graded the expression levels as negative, weak positive and strong positive (see Supplementary section).
Methylation-specific PCR
We analysed prostate cancer, BPHs and normal prostate tissue samples. DNA was extracted and denatured with NaOH and treated with sodium bisulfite for 16 h. We used the following MSP primers: unmethylated TIMP-2 sense: 5 0 -TTTGGTGT TTTGGAAGAATGGGTG-3 0 and antisense 5 0 -CCAACCCC AATCCCCACTACA-3 0 ; methylated TIMP-2 sense: 5 0 -TTTG GTGTTTTGGAAGAACGGGCG-3 0 and antisense 5 0 -CGA CCCCGATCCCCGCTACG-3 0 . Positive controls used for MSP included DNA from RWPE1 cells as the unmethylated DNA control and CpGenome Universal methylated DNA as the methylated DNA control (Chemicon, Temecula, CA, USA). Negative control MSP reactions were performed using water only as template.
Cloning and bisulfite sequencing
To permit DNA sequencing of inclusive CpG sites within the CpG island of the TIMP-2 gene, sodium bisulfite-treated DNA A filled circle represents a methylated CG dinucleotide, and an empty circle represents a demethylated CG dinucleotide. (a) DNAs of ten normal prostate and prostate tumor samples that displayed methylated TIMP-2 in tumor (T) and unmethylated TIMP-2 in normal prostate tissue (N) was selected for genomic sequencing; the selected prostate tumor samples were negative in TIMP-2 protein expression. (b) DNAs of ten normal adjacent tissue (NAT) samples that displayed unmethylated TIMP-2 in assays of MSP and their tumor counterparts displayed decreased TIMP-2 expression in realtime PCR analysis were selected for genomic sequencing.
was amplified with primers common to methylated and unmethylated DNA sequences. Amplified PCR products were purified with a Gel extraction kit (Qiagen, Valencia, CA, USA) and ligated into pCR2.1-TOPO plasmid vector with a TAcloning system (Invitrogen, Carlsbad, CA, USA). Plasmidtransformed Escherichia coli were cultured and plasmid DNA was isolated with FastPlasmid mini-prep kit (Eppendorf, Westbury, NY, USA). Purified plasmid DNA containing the TIMP-2 sequence was sequenced with an automated DNA sequencer. Bisulfite sequencing was performed in 10 prostate cancer samples, 10 matched non-neoplastic adjacent tissues and 10 normal prostate samples. Samples that had clones with >50% methylation of CpGs were designated partially methylated. Samples containing clones with >75% methylation of CpGs sites were designated methylation-positive. All other samples were designated methylation-negative.
Immunoblot, ChIP and RT-PCR analysis
Immunoblotting, ChIP and RT-PCR were performed as described previously (Pulukuri and Rao, 2006) . Expression analysis for TIMP-2 mRNA was measured using real-time quantitative PCR with SYBR Green PCR Mastermix (Bio-Rad, Hercules, CA, USA) (see Supplementary section).
Matrigel invasion assay
Invasion of cells through matrigel was conducted using a Transwell apparatus (Corning Costar) as described previously (Yoon et al., 2001 ) (see Supplementary section).
